PDA Cost Considerations
Medical-review status: A licensed medical reviewer has not yet been assigned to this page. Until one is, the page is published as an editorial draft and is not presented as medically reviewed. See our medical review policy.
Quick answer
PDA is typically sold through compounding-based telehealth programs at prices that vary widely. Because PDA is not FDA-approved and is not proven effective, cost should be weighed against significant evidence and safety uncertainty, in U.S. dollars.
This page discusses cost transparency, not effectiveness. PDA is not FDA-approved. (No direct study of Pentadeca Arginate was found for this statement.)
Read this before comparing prices
Cost is not value
No direct evidence identifiedA price does not indicate that a product works or is safe. Pentadeca Arginate has no human effectiveness evidence and is not FDA-approved.[1],[2]
Advertisement slot — inactive
Ads are not enabled until the site is editorially and technically ready.
What a U.S. price should disclose
If you encounter PDA pricing, look for clear disclosure (all figures in USD) of what is and is not included:
- The date the price was checked
- Whether a consultation fee, medication, lab testing, or shipping is included
- Whether a subscription is required and whether the price is introductory
- Whether insurance is accepted
- Whether the product is compounded or FDA-approved (PDA is not FDA-approved)
- Whether pricing differs by dose or by state
Compounded is not "generic"
A compounded peptide is not a generic version of an FDA-approved drug, and should not be described that way. Compounded products are not FDA-reviewed for safety, effectiveness, or quality.[1]
Frequently asked questions
How much does PDA cost?
Prices vary by provider and program and change over time. Any price should be shown in USD with clear disclosure of what is included; cost does not reflect proven effectiveness.
References
3 peer-reviewed journal sources and 2 additional authoritative references. Every reference supports a specific statement above.
- [1] U.S. Food and Drug Administration (2025). Bulk drug substances used in compounding under section 503A of the FD&C Act. FDA.gov, Regulatory information (compounding). View source Government / regulatory
- [2] Operation Supplement Safety (U.S. Department of Defense) (2024). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. OPSS.org (DoD), U.S. government consumer-safety advisory. View source Government / regulatory
- [3] Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2):153–159. View source Peer-reviewed journal
- [4] Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal (SAGE), Systematic review. View source Peer-reviewed journal
- [5] Current Reviews in Musculoskeletal Medicine (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, Narrative review. View source Peer-reviewed journal